Achieve Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2020

Summary of Assets Measured at Fair Value on Recurring Basis

The following table presents information about our assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

March 31, 2020	Level 1		Level 2		Level 3		Total
Assets
Cash	$	550	$	—	$	—	$	550
Money market securities (cash equivalents)		11,606		—		—		11,606
Restricted cash		50		—		—		50
Total assets	$	12,206	$	—	$	—	$	12,206

Summary of Cash and Cash Equivalents

Cash and cash equivalents consist of the following (in thousands):

			Gross		Gross
			Unrealized		Unrealized		Estimated
March 31, 2020	Cost		Gains		Losses		Fair Value
Cash	$	550	$	—	$	—	$	550
Money market securities		11,606		—		—		11,606
Total cash and cash equivalents	$	12,156	$	—	$	—	$	12,156
Money market securities (restricted cash)		50		—		—		50
Total restricted cash	$	50	$	—	$	—	$	50